The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis

MLA

Christian S. Thudium, et al. “The Janus Kinase 1/2 Inhibitor Baricitinib Reduces Biomarkers of Joint Destruction in Moderate to Severe Rheumatoid Arthritis.” Arthritis Research & Therapy, vol. 22, no. 1, Oct. 2020, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s13075-020-02340-7.

APA

Christian S. Thudium, Anne C. Bay-Jensen, Suntara Cahya, Ernst R. Dow, Morten A. Karsdal, Alisa E. Koch, Wenling Zhang, & Robert J. Benschop. (2020). The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis. Arthritis Research & Therapy, 22(1), 1–11. https://doi.org/10.1186/s13075-020-02340-7

Chicago

Christian S. Thudium, Anne C. Bay-Jensen, Suntara Cahya, Ernst R. Dow, Morten A. Karsdal, Alisa E. Koch, Wenling Zhang, and Robert J. Benschop. 2020. “The Janus Kinase 1/2 Inhibitor Baricitinib Reduces Biomarkers of Joint Destruction in Moderate to Severe Rheumatoid Arthritis.” Arthritis Research & Therapy 22 (1): 1–11. doi:10.1186/s13075-020-02340-7.